Aastrom - Page 3 - Ventures & Markets - LONGECITY

ImmInst 01 Jun 2011

Trial results expected from Aastrom Biosciences
BioMedReports - 2 hours ago

about 6 minutes ago Trial results expected from Aastrom Biosciences: Aastrom Biosciences, Inc. (Nasdaq:ASTM) the leading developer ... http://bit.ly/m2v835 about 10 hours ago Aegerion Announces ...

View the full article

Quote

ImmInst 13 Jun 2011

Stem Cell Stocks Remain Some of the Most Volatile in the Market
Marketwire - 1 hour ago

NEW YORK, NY--(Marketwire - Jun 13, 2011) - Stem Cell stocks continue to be some of the most volatile in the market. While scientists firmly believe that stem cells are the future of medicine, and ...

View the full article

Quote

ImmInst 16 Jun 2011

Aastrom Files At-the-Market Offering and New Shelf Registration Statement
MarketWatch - 22 hours ago

ANN ARBOR, Mich., Jun 16, 2011 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. /quotes/zigman/116807/quotes/nls/astm ASTM -2.02% , the leading developer of patient-specific, expanded ...

View the full article

Quote

ImmInst 21 Jun 2011

Aastrom Establishes Independent Steering Committee for REVIVE Phase 3 CLI Clinical Program
MarketWatch - 18 hours ago

ANN ARBOR, Mich., Jun 21, 2011 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. /quotes/zigman/116807/quotes/nls/astm ASTM +2.73% , the leading developer of patient-specific, expanded ...

Aastrom Biosciences (ASTM) Forms Independent Steering Committee for REVIVE Phase 3 CLI Clinical Program - StreetInsider.com
Aastrom Forms Independent Committee For REVIVE Phase 3 CLI Clinical Program - RTT News

View the full article

Quote

ImmInst 23 Jun 2011

Journal of Vascular Surgery Publishes Interim Results of RESTORE-CLI Phase 2b Clinical Trial
MarketWatch - 2 hours ago

ANN ARBOR, Mich., Jun 23, 2011 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. /quotes/zigman/116807/quotes/nls/astm ASTM +3.52% , the leading developer of patient-specific, expanded ...

View the full article

Quote

ImmInst 24 Jun 2011

Healthcare Stocks Looking Up, ATRC, ASTM, GTIV, ENZ
The Markets Are Open - 4 hours ago

AtriCure Inc. (ATRC) shares was up 2.55% today, moving to $12.45 per share. Stock volume in AtriCure Inc. was 24,204 shares in the trading session. Aastrom Biosciences, Inc. (ASTM) shares pressed ...

Gains in Healthcare Sector (ENZ) (ACHN) (GTIV) (ASTM) - Tickr Watch

View the full article

Quote

ImmInst 27 Jun 2011

The Long And Short Of Aastrom Biosciences
RTT News - 2 hours ago

(RTTNews) - As regenerative medicine company Aastrom Biosciences Inc. (ASTM: News ) continues to make progress with its ongoing clinical trial programs, there are a couple of events coming up in ...

View the full article

Quote

ImmInst 30 Jun 2011

Bouncing Back from the Dark Side: ASTM, GIGM, BPAX
Small Cap Network - 2 hours ago

By Dennis Askew Taking a look at Aastrom Biosciences Inc (NASDAQ: ASTM), BioSante Pharmaceuticals Inc (NASDAQ: BPAX), and GigaMedia Ltd (NASDAQ: GIGM) certainly inspires hope. Sometimes it's very ...

View the full article

Quote

ImmInst 22 Jul 2011

Climbing Back Up the Hill of Share Value: ASTM, OWW, PSUN
Small Cap Network - 1 hour ago

Getting out of the Red Day by Day and a Few Cents at a Time. By Dennis Askew This grouping of companies, Aastrom Biosciences Inc (NASDAQ: ASTM), Orbitz Worldwide Inc (NYSE: OWW), and Pacific ...

View the full article

Quote

ImmInst 25 Jul 2011

Can They Keep the Momentum Going? LRAD, ASTM, CBB
Small Cap Network - 2 hours ago

By Dennis Askew The following three companies, LRAD Corporation (NASDAQ: LRAD), Aastrom Biosciences Inc (NASDAQ: ASTM), and Cincinnati Bell Inc (NYSE: CBB), have all had a good month, spurred on ...

View the full article

Quote

ImmInst 26 Jul 2011

Aastrom Announces Agreement From FDA on Special Protocol Assessment for Phase 3 Clinical Trial in No-Option Critical Limb Ischemia Patients
MarketWatch - 7 minutes ago

ANN ARBOR, Mich., Jul 26, 2011 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. /quotes/zigman/116807/quotes/nls/astm ASTM +1.40% , the leading developer of patient-specific, expanded ...

View the full article

Quote

ImmInst 26 Jul 2011

Coronado readies IND for Crohn's treatment; Aastrom reaches agreement on SPA for critical limb ischemia study;
FierceBiotech - 2 hours ago

@JohnCFierce: Under pressure to speed things up, FDA Commissioner Margaret Hamburg is looking to loosen conflict rules for adcomm members. Report | Follow @JohnCFierce @RyanMFierce: Icon's buyout ...

View the full article

Quote

ImmInst 26 Jul 2011

Needham & Company Maintains a 'Buy' on Aastrom Biosciences (ASTM); SPA in the Summer Worth the Wait - Phase 3 Stem Cell Ixmyelocel-T Trial
StreetInsider.com - 2 hours ago

Needham analyst says, "This morning, Aastrom announced an agreement with the FDA on the Special Protocol Assessment (SPA) for ... StreetInsider.com provides up-to-the-minute active trading news ...

View the full article

Quote

ImmInst 09 Aug 2011

Aastrom Enters Final-Stage Trial With Stem-Cell Therapy for CLI Patients
Xconomy - 2 hours ago

â€œThe FDA encouraged us to pursue this [Special Protocol Assessment] process since there aren'ta lot of new therapies for iscemia,â€ said Aastrom CEO Tim Mayleben. â€œThe Special Protocol Assessment ...

View the full article

Quote

ImmInst 12 Aug 2011

Global Hunter Securities Starts Aastrom Biosciences (ASTM) at Speculative Buy; Ixmyelocel-T a Potentially Significant Driver
StreetInsider.com - 1 minute ago

Global Hunter Securities initiates coverage on Aastrom Biosciences (NASDAQ: ASTM) with a Speculative Buy. PT $6.00. Global analyst says, "ASTM is developing cell-based therapies for use in the ...

View the full article

Quote

ImmInst 12 Aug 2011

MultiCell Technology and Aastrom Biosciences Aim to Shatter Stem Cell Myths
PR-USA.net - 2 hours ago

With Americans spending in excess of $300 billion annually on drugs which typically only treat disease symptoms, regenerative therapies are garnering increased support. Scientists argue that stem ...

View the full article

Quote

ImmInst 11 Aug 2011

Aastrom Announces Adoption of Shareholder Rights Plan
MarketWatch - 20 hours ago

ANN ARBOR, Mich., Aug 11, 2011 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. /quotes/zigman/116807/quotes/nls/astm ASTM +6.73% ("Aastrom" or the "Company"), the leading developer of ...

Global Hunter Securities Starts Aastrom Biosciences (ASTM) at Speculative Buy; Ixmyelocel-T a Potentially Significant Driver - StreetInsider.com

View the full article

Quote

ImmInst 14 Aug 2011

6 Recently Crushed Stocks With Heavy New Insider Buying
Seeking Alpha - 17 hours ago

A major market correction is creating some new stock bargains that insiders are taking advantage of at several companies. The amount of insider buying has surged in the last few days, and a new ...

View the full article

Quote

ImmInst 25 Aug 2011

EPS below consensus: ASTM, KH, HTHT
Rapid News Network - 23 minutes ago

Aastrom Biosciences, Inc. (Public, NASDAQ:ASTM). Last Market Price: 2.47, Change: +0.03, % Change: (1.23%). Shares trade in the range of 2.37 â€“ 2.51 dollars. It has a market capitalization of 95 ...

View the full article

Quote

ImmInst 14 Sep 2011

Aastrom to Present 12-Month Data From the IMPACT-DCM Phase 2 Clinical Trial for Ixmyelocel-T in Treatment of Dilated Cardiomyopathy
MarketWatch - 3 hours ago

ANN ARBOR, Mich., Sep 14, 2011 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. /quotes/zigman/116807/quotes/nls/astm ASTM +1.24% , a leading developer of patient-specific, expanded ...

Aastrom Biosciences (ASTM) to Present Ixmyelocel-T Data - StreetInsider.com

View the full article

Quote

ImmInst 15 Dec 2010

Aastrom Biosciences, Inc. Closes $22.5 Million Public Offering
Reuters Key Development - Dec 15, 2010

View the full article

Quote

ImmInst 19 Sep 2011

Aastrom Announces Positive 12-Month Safety and Efficacy Data From IMPACT-DCM Phase 2 Clinical Trial for Ixmyelocel-T in Treatment of Dilated Cardiomyopathy
TradersHuddle.com - 2 hours ago

ANN ARBOR, Mich., Sept. 19, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of ...

View the full article

Quote

ImmInst 23 Sep 2011

Aastrom to Present at the Sixth Annual JMP Securities Healthcare Conference
MarketWatch - 1 hour ago

ANN ARBOR, Mich., Sep 23, 2011 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. /quotes/zigman/116807/quotes/nls/astm ASTM 0.00% , the leading developer of patient-specific, expanded ...

View the full article

Quote

ImmInst 03 Oct 2011

Aastrom Granted European Composition-of-Matter Patent for Ixmyelocel-T
MarketWatch - 2 hours ago

ANN ARBOR, Mich., Oct 3, 2011 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. /quotes/zigman/116807/quotes/nls/astm ASTM -3.12% , the leading developer of patient-specific, expanded ...

Aastrom Bio (ASTM) Receives Patent Protection for Ixmyelocel-T in EU - StreetInsider.com

View the full article

Quote

ImmInst 04 Oct 2011

Investors look to Lighten Up on Shares of Aastrom Biosciences, Shares Down 2.3% (ASTM)
Financial News Network Online - 2 hours ago

Aastrom Biosciences (NASDAQ:ASTM) is one of today's worst performing low-priced stocks, down 2.3% to $2.11 on 0.9x average daily volume.Thus far today, Aastrom Biosciences has traded 208,000 ...

View the full article

Quote

ImmInst 13 Oct 2011

Aastrom Appoints Brian Gibson as Vice President, Finance
MarketWatch - 21 hours ago

ANN ARBOR, Mich., Oct 13, 2011 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. /quotes/zigman/116807/quotes/nls/astm ASTM 0.00% , the leading developer of patient-specific, expanded ...

Aastrom Biosciences (ASTM) Names Brian Gibson as Chief Accounting Officer and Treasurer - StreetInsider.com
AASTROM BIOSCIENCES, INC.: Aastrom Appoints Brian Gibson as Vice President.. - 4-traders

View the full article

Quote

ImmInst 24 Oct 2011

Leg-saving cell therapy
Stockopedia - 1 hour ago

Oct 24th 2011 - Edison Investment Research today published a report on Aastrom Biosciences entitled "Leg-saving Cell Therapy". In summary, the report says: Aastrom has developed a patient-specific ...

View the full article

Quote

ImmInst 24 Oct 2011

Werner (WERN) (AGPPY) (ASTM) (CMRE) (DM) (DSX) Get New Coverage
Everything Gold - 3 hours ago

Werner Enterprises, Inc. (NASDAQ: WERN), Anglo Platinum Limited (OTC: AGPPY), Aastrom Biosciences Inc. (NASDAQ: ASTM), Comstock Resources (NASDAQ: CMRE), The Dolan Company (NYSE: DM) and Diana ...

View the full article

Quote

ImmInst 24 Oct 2011

Edison Expands Cell Therapy Sector Presence with Launch of Research Coverage on Aastrom
MarketWatch - 5 hours ago

LONDON, Oct 24, 2011 (BUSINESS WIRE) -- Edison Investment Research, a UK-based independent equity research firm, announces the initiation of research coverage on Aastrom Biosciences, Inc /quotes ...

Leg-saving cell therapy - Stockopedia

View the full article

Quote

ImmInst 25 Oct 2011

6 Biotech Stocks Undervalued By Their Levered Free Cash Flows
Seeking Alpha - 16 minutes ago

Contrary to what you may expect, many publicly traded biotech firms do not yet produce significant cash flows. This is because many biotechs are developing products but do not yet have a drug on ...

View the full article

Quote